Skip to main navigation Skip to main content Skip to footer For Individuals & Families For Medicare For Providers For Brokers Español For Employers: For Employers Medical Savings and Spending Accounts (HRA/HSA/FSA) Wellness, Mental Health, and Behavioral Pharmacy Dental and Vision Cost Control Strategies Supplemental Health Solutions Who We Serve Overview Small Employers (51 - 499) Medium Employers (500 - 2,999) Large Employers (3,000+) Hospitals and Health Systems Higher Education K-12 Education State and Local Governments Taft-Hartley and Federal Membership and Affinity Groups Third Party Administrators Health Insurance for Expats IGO/NGOs Multinational Businesses Why Cigna Overview Industry Insights Overview Informed on Reform Workplace Wellness Consumer-Driven Health Plans Log in to Employer Portal
Home Employers Cost Control StrategiesEmbarc Benefit Protection

Embarc Benefit Protection®

Our unique network solution helps ensure access to breakthrough gene therapy drugs while offering protection from high costs.

Connect with Us

We are leading the way by connecting access, innovation, and experience.

By 2030, annual gene therapy sales in the United States are expected to reach $15.68 billion.1 If health plans cannot afford to cover these drugs, the patients that need them will not have access.

Embarc Benefit Protection

The Embarc Benefit Protection solution offers an answer to this impending crisis. It brings together the health services, medical management, and specialty pharmacy expertise of Cigna, eviCore, Accredo, and Express Scripts. This solution helps shield health plans and customers from the high cost of breakthrough gene therapy drugs and helps to ensure access for those who need them.

The solution includes:

  • LUXTURNA® (voretigene neparvovec-rzyl): The first FDA-approved prescription gene therapy for people with inherited retinal disease
  • ZOLGENSMA® (onasemnogene abeparvovec-xioi)2: A gene therapy for children under 2 years old with spinal muscular atrophy
  • ZYNTELGO® (betibeglogene autotemcel)3: Used for a blood disorder known as beta thalassemia in patients who cannot make enough beta-globin and require regular red blood cell transfusions at a cost of $2.8M
  • SKYSONA® (elivaldogene autotemcel): With a cost of $3M, this gene therapy is for patients 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD) - a rare neuro-degenerative disease that can lead to progressive, irreversible loss of neurologic function and death
  • HEMGENIX® (etranacogene dezaparvovec-drlb)4: A one-time gene therapy drug with a projected cost of $3.5M for adults living with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes
  • Additional therapies may be added in the future

Like our recent advances with our Patient Assurance ProgramSM and digital health formulary, the Embarc Benefit Protection solution is another great example of what our combined company can do for our clients and customers. Employers, health plans, and unions can have the peace of mind that comes from being better protected against the high costs associated with new breakthrough therapies.

Let's Get Started

Thank you for your interest in Cigna. Please provide some basic information about your company and a representative will contact you.

Processing your submission...

Learn more about the Embarc Benefit Protection solution and potentially life changing treatments.

Contact your Cigna representative for more information.

Connect with us

More Cost Control Strategies

Funding Solutions Medical Stop Loss Insurance Defined Contributions

View Cigna Company Names

1Precedence Research, Gene Therapy Market Size, Growth, Trends, Report 2021-2030,, accessed August 18, 2022

2The financial protection against the high cost of ZOLGENSMA applies only to children born after the Embarc Benefit Protection solution is effective for their group health plan.

3For existing Embarc Benefit Protection clients with effective dates of 08/01/2022 or earlier, all members who meet the solution’s clinical and network criteria for ZYNTEGLO will be able to access the drug through Embarc Benefit Protection. For clients who join Embarc Benefit Protection after 08/01/2022, Embarc Benefit Protection for ZYNTEGLO is only applicable to members who first became eligible for coverage under the Plan on and after 08/19/2022.

4For existing Embarc Benefit Protection clients with effective dates of March 1, 2023 or earlier, all customers who meet the solution’s clinical and network criteria for HEMGENIX will be able to access the drug through Embarc Benefit Protection. For clients that join Embarc Benefit Protection after March 1, 2023, the financial protection extends only to customers who join the underlying medical coverage 30 days or more after the client is effective in Embarc Benefit Protection (i.e., late enrollees).

Product availability may vary by location and plan type and is subject to change. For costs and details contact a Cigna representative.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including eviCore healthcare MSI, LLC (d/b/a/ eviCore healthcare), Express Scripts, Inc., Accredo Health Group, Inc., or their affiliates. LUXTURNA is the registered trademark of Spark Therapeutics, Inc. and ZOLGENSMA is the registered trademark of AveXis, Inc. ZYNTEGLO and SKYSONA are both registered trademarks of bluebird bio, Inc. HEMGENIX is the registered trademark of CSL Behring, L.L.C.

© 2023 Cigna. Some content provided under license

Page Footer

I want to...

Get an ID card File a claim View my claims and EOBs Check coverage under my plan See prescription drug list Find an in-network doctor, dentist, or facility Find a form Find 1095-B tax form information View the Cigna Glossary Contact Cigna


Individuals and Families Medicare Employers Brokers Providers

Secure Member Sites

myCigna member portal Health Care Provider portal Cigna for Employers Client Resource Portal Cigna for Brokers

The Cigna Group Information

About The Cigna Group Company Profile Careers Newsroom Investors Suppliers The Cigna Group Third Party Administrators International Evernorth

 Cigna. All rights reserved.

Privacy Legal Product Disclosures Cigna Company Names Customer Rights Accessibility Report Fraud Sitemap


Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of South Carolina, Inc., and Cigna HealthCare of Texas, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see a listing of the legal entities that insure or administer group HMO, dental HMO, and other products or services in your state). Accidental Injury, Critical Illness, and Hospital Care plans or insurance policies are distributed exclusively by or through operating subsidiaries of Cigna Corporation, are administered by Cigna Health and Life Insurance Company, and are insured by either (i) Cigna Health and Life Insurance Company (Bloomfield, CT); (ii) Life Insurance Company of North America (“LINA”) (Philadelphia, PA); or (iii) New York Life Group Insurance Company of NY (“NYLGICNY”) (New York, NY), formerly known as Cigna Life Insurance Company of New York. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. LINA and NYLGICNY are not affiliates of Cigna.

All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico.

Selecting these links will take you away from to another website, which may be a non-Cigna website. Cigna may not control the content or links of non-Cigna websites. Details